{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:56:06Z","timestamp":1793933766844,"version":"4.8.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amyloidosis Research Consortium"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Fam Pract"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transthyretin amyloidosis (also known as ATTR amyloidosis) is a systemic, life-threatening disease characterized by transthyretin (TTR) fibril deposition in organs and tissue. A definitive diagnosis of ATTR amyloidosis is often a challenge, in large part because of its heterogeneous presentation. Although ATTR amyloidosis was previously considered untreatable, disease-modifying therapies for the treatment of this disease have recently become available. This article aims to raise awareness of the initial symptoms of ATTR amyloidosis among general practitioners to facilitate identification of a patient with suspicious signs and symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>These consensus recommendations for the suspicion and diagnosis of ATTR amyloidosis were developed through a series of development and review cycles by an international working group comprising key amyloidosis specialists. This working group met to discuss the barriers to early and accurate diagnosis of ATTR amyloidosis and develop a consensus recommendation through a thorough search of the literature performed using PubMed Central.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cardiac and peripheral nervous systems are most frequently involved in ATTR amyloidosis; however, many patients often also experience gastrointestinal and other systemic manifestations. Given the multisystemic nature of symptoms, ATTR amyloidosis is often misdiagnosed as a more common disorder, leading to significant delays in the initiation of treatment. Although histologic evaluation has been the gold standard to confirm ATTR amyloidosis, a range of tools are available that can facilitate early and accurate diagnosis. Of importance, genetic testing should be considered early in the evaluation of a patient with unexplained peripheral neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A diagnostic algorithm based on initial red flag symptoms and manifestations of cardiac or neurologic involvement will facilitate identification by the general practitioner of a patient with clinically suspicious symptoms, enabling subsequent referral of the patient to a multidisciplinary specialized medical center.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12875-020-01252-4","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T12:03:24Z","timestamp":1600862604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Melo","family":"Beir\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahat","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Drachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnt V.","family":"Kristen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole B.","family":"Suhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Nativi-Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida Cristina","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Rapezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"1","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Conceicao","year":"2016","unstructured":"Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. \"red-flag\" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5\u20139.","journal-title":"J Peripher Nerv Syst"},{"issue":"9","key":"1252_CR2","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1073\/pnas.75.9.4499","volume":"75","author":"PP Costa","year":"1978","unstructured":"Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S A. 1978;75(9):4499\u2013503.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1252_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1172\/JCI111390","volume":"74","author":"MJ Saraiva","year":"1984","unstructured":"Saraiva MJ, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest. 1984;74(1):104\u201319.","journal-title":"J Clin Invest"},{"issue":"2\u20133","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0014-5793(01)02480-2","volume":"498","author":"MJ Saraiva","year":"2001","unstructured":"Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett. 2001;498(2\u20133):201\u20133.","journal-title":"FEBS Lett"},{"key":"1252_CR5","volume-title":"A Physician's guide to Transthyretin amyloidosis","author":"T Coelho","year":"2008","unstructured":"Coelho T, Ericzon BG, Falk R, Grogen D. A Physician's guide to Transthyretin amyloidosis; 2008."},{"issue":"13","key":"1252_CR6","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1021\/acs.biochem.6b00164","volume":"55","author":"KH Lim","year":"2016","unstructured":"Lim KH, Dasari AK, Hung I, Gan Z, Kelly JW, Wemmer DE. Structural changes associated with Transthyretin Misfolding and amyloid formation revealed by solution and solid-state NMR. Biochemistry. 2016;55(13):1941\u20134.","journal-title":"Biochemistry"},{"issue":"4","key":"1252_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","volume":"25","author":"MD Benson","year":"2018","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215\u20139.","journal-title":"Amyloid"},{"issue":"2","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222\u20138.e1.","journal-title":"Am Heart J"},{"issue":"3","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"LH Connors","year":"2016","unstructured":"Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type Transthyretin: a prospective, Observational Cohort Study. Circulation. 2016;133(3):282\u201390.","journal-title":"Circulation"},{"issue":"9","key":"1252_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120\u20137.","journal-title":"Eur Heart J"},{"issue":"2","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/13506129.2018.1474734","volume":"25","author":"H Koike","year":"2018","unstructured":"Koike H, Yasuda T, Nishi R, Ikeda S, Kawagashira Y, Iijima M, et al. Systemic angiopathy and axonopathy in hereditary transthyretin amyloidosis with Ala97Gly (p. Ala117Gly) mutation: a post-mortem analysis. Amyloid. 2018;25(2):141\u20132.","journal-title":"Amyloid"},{"issue":"2","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","volume":"22","author":"PL Swiecicki","year":"2015","unstructured":"Swiecicki PL, Zhen DB, Mauermann ML, Kyle RA, Zeldenrust SR, Grogan M, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22(2):123\u201331.","journal-title":"Amyloid"},{"issue":"2","key":"1252_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of Transthyretin cardiac amyloidosis: THAOS (Transthyretin amyloid outcome survey). J Am Coll Cardiol. 2016;68(2):161\u201372..","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1252_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","volume":"83","author":"H Koike","year":"2012","unstructured":"Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83(2):152\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type Transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"1252_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"issue":"7 Suppl","key":"1252_CR17","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107\u2013S12.","journal-title":"Am J Manag Care"},{"issue":"1","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS - the Transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1252_CR19","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286\u2013300.","journal-title":"Circulation"},{"key":"1252_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis. 2014;9:61.","journal-title":"Orphanet J Rare Dis"},{"key":"1252_CR21","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.autneu.2019.102590","volume":"222","author":"A Gonzalez-Duarte","year":"2019","unstructured":"Gonzalez-Duarte A, Barroso F, Mundayat R, Shapiro B. Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS). Auton Neurosci. 2019;222:102590.","journal-title":"Auton Neurosci"},{"issue":"17","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","volume":"72","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72(17):2040\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1252_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/03009734.2014.895786","volume":"119","author":"P Westermark","year":"2014","unstructured":"Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014;119(3):223\u20138.","journal-title":"Ups J Med Sci"},{"issue":"2","key":"1252_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/13506129.2011.565524","volume":"18","author":"H Koike","year":"2011","unstructured":"Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid. 2011;18(2):53\u201362.","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"1252_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/13506129.2012.685665","volume":"19","author":"D Adams","year":"2012","unstructured":"Adams D, Lozeron P, Theaudin M, Mincheva Z, Cauquil C, Adam C, et al. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid. 2012;19(Suppl 1):61\u20134.","journal-title":"Amyloid"},{"issue":"1","key":"1252_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","volume":"23","author":"M Nakagawa","year":"2016","unstructured":"Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23(1):58\u201363.","journal-title":"Amyloid"},{"issue":"10","key":"1252_CR27","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jhsa.2019.06.016","volume":"44","author":"JP Donnelly","year":"2019","unstructured":"Donnelly JP, Hanna M, Sperry BW, Seitz WH Jr. Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis. J Hand Surg [Am]. 2019;44(10):868\u201376.","journal-title":"J Hand Surg [Am]"},{"issue":"9","key":"1252_CR28","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.humpath.2010.11.017","volume":"42","author":"T Sueyoshi","year":"2011","unstructured":"Sueyoshi T, Ueda M, Jono H, Irie H, Sei A, Ide J, et al. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol. 2011;42(9):1259\u201364.","journal-title":"Hum Pathol"},{"issue":"11","key":"1252_CR29","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"1252_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary Transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"1252_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary Transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1252_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232\u20139.","journal-title":"Ann Med"},{"issue":"2","key":"1252_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113\u201322.","journal-title":"JACC Heart Fail"},{"issue":"38","key":"1252_CR34","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585\u201394.","journal-title":"Eur Heart J"},{"issue":"38","key":"1252_CR35","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879\u201387.","journal-title":"Eur Heart J"},{"issue":"2","key":"1252_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s004390050199","volume":"98","author":"DR Jacobson","year":"1996","unstructured":"Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet. 1996;98(2):236\u20138.","journal-title":"Hum Genet"},{"issue":"2","key":"1252_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13506120500107162","volume":"12","author":"T Yamashita","year":"2005","unstructured":"Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid. 2005;12(2):127\u201330.","journal-title":"Amyloid"},{"issue":"7","key":"1252_CR38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2016.200","volume":"19","author":"JN Buxbaum","year":"2017","unstructured":"Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017;19(7):733\u201342.","journal-title":"Genet Med"},{"issue":"3","key":"1252_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","volume":"22","author":"DR Jacobson","year":"2015","unstructured":"Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22(3):171\u20134.","journal-title":"Amyloid"},{"key":"1252_CR40","volume-title":"Quick Facts United States. Population estimates, July 1, 2018 (V2018)","author":"UC Bureau","year":"2018","unstructured":"Bureau UC. Quick Facts United States. Population estimates, July 1, 2018 (V2018). https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045218. Washington, DC: US Census Bureau; 2018."},{"issue":"8","key":"1252_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625\u201338.","journal-title":"Ann Med"},{"issue":"Suppl 1","key":"1252_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/13506129.2012.674580","volume":"19","author":"H Koike","year":"2012","unstructured":"Koike H, Sobue G. Late-onset familial amyloid polyneuropathy in Japan. Amyloid. 2012;19(Suppl 1):55\u20137.","journal-title":"Amyloid"},{"issue":"5","key":"1252_CR43","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hopps M, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829\u201337.","journal-title":"Muscle Nerve"},{"issue":"21","key":"1252_CR44","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of Transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451\u201366.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"1252_CR45","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14\u201326.","journal-title":"Curr Opin Neurol"},{"issue":"Suppl 1","key":"1252_CR46","doi-asserted-by":"publisher","first-page":"P22","DOI":"10.1186\/1750-1172-10-S1-P22","volume":"10","author":"I Lousada","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium. Orphanet J Rare Dis. 2015;10(Suppl 1):P22 P.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1252_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac Transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326.","journal-title":"Circulation"},{"issue":"2","key":"1252_CR48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/modpathol.2014.102","volume":"28","author":"A Yanagisawa","year":"2015","unstructured":"Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015;28(2):201\u20137.","journal-title":"Mod Pathol"},{"issue":"Suppl 1","key":"1252_CR49","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","volume":"29","author":"L Obici","year":"2016","unstructured":"Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29(Suppl 1):S27\u201335.","journal-title":"Curr Opin Neurol"},{"key":"1252_CR50","doi-asserted-by":"crossref","unstructured":"Yarlas A, Gertz MA, Dasgupta NR, Obici L, Pollock M, Ackermann EJ, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019;60:169\u201375.","DOI":"10.1002\/mus.26515"},{"issue":"2","key":"1252_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","volume":"7","author":"M Stewart","year":"2018","unstructured":"Stewart M, Shaffer S, Murphy B, Loftus J, Alvir J, Cicchetti M, et al. Characterizing the high disease burden of Transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018;7(2):349\u201364.","journal-title":"Neurol Ther"},{"issue":"14","key":"1252_CR52","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357\u201377.","journal-title":"Circulation"},{"issue":"9","key":"1252_CR53","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of Transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.","journal-title":"Circ Heart Fail"},{"key":"1252_CR54","doi-asserted-by":"crossref","unstructured":"Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9e005066.","DOI":"10.1161\/CIRCIMAGING.116.005066"},{"issue":"13 Supplement","key":"1252_CR55","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0735-1097(16)31536-4","volume":"67","author":"A Castano","year":"2016","unstructured":"Castano A, Narotsky D, Kodali S, Nazif T, George I, Vahl T, et al. Transthyretin cardiac amyloidosis is prevalent among men with severe aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;67(13 Supplement):1535.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"1252_CR56","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T, Costes B, Hagege AA, Donal E, Eicher JC, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826\u201334.","journal-title":"Eur Heart J"},{"issue":"1","key":"1252_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12947-016-0072-5","volume":"14","author":"VM Parato","year":"2016","unstructured":"Parato VM, Antoncecchi V, Sozzi F, Marazia S, Zito A, Maiello M, et al. Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy. Cardiovasc Ultrasound. 2016;14(1):30.","journal-title":"Cardiovasc Ultrasound"},{"issue":"2","key":"1252_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","volume":"20","author":"C Rapezzi","year":"2015","unstructured":"Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015;20(2):117\u201324.","journal-title":"Heart Fail Rev"},{"issue":"3","key":"1252_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/13506129.2015.1037831","volume":"22","author":"S Gustavsson","year":"2015","unstructured":"Gustavsson S, Granasen G, Gronlund C, Wiklund U, Morner S, Henein M, et al. Can echocardiography and ECG discriminate hereditary transthyretin V30M amyloidosis from hypertrophic cardiomyopathy? Amyloid. 2015;22(3):163\u201370.","journal-title":"Amyloid"},{"issue":"6","key":"1252_CR60","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1252_CR61","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.880150416","volume":"15","author":"Y Ando","year":"1992","unstructured":"Ando Y, Araki S, Shimoda O, Kano T. Role of autonomic nerve functions in patients with familial amyloidotic polyneuropathy as analyzed by laser Doppler flowmetry, capsule hydrograph, and cardiographic R-R interval. Muscle Nerve. 1992;15(4):507\u201312.","journal-title":"Muscle Nerve"},{"issue":"19","key":"1252_CR62","doi-asserted-by":"publisher","first-page":"e1834","DOI":"10.1212\/WNL.0000000000006474","volume":"91","author":"T Masuda","year":"2018","unstructured":"Masuda T, Ueda M, Kitajima M, Morita K, Misumi Y, Yamashita T, et al. Teaching NeuroImages: morphology of lumbosacral dorsal root ganglia and plexus in hereditary transthyretin amyloidosis. Neurology. 2018;91(19):e1834\u2013e5.","journal-title":"Neurology"},{"issue":"11","key":"1252_CR63","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","volume":"25","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Card Fail. 2019;25(11):e1\u2013e39.","journal-title":"J Card Fail"},{"issue":"11","key":"1252_CR64","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.cardfail.2019.08.002","volume":"25","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Card Fail. 2019;25(11):854\u201365.","journal-title":"J Card Fail"},{"issue":"3","key":"1252_CR65","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/ene.13845","volume":"26","author":"M Theaudin","year":"2019","unstructured":"Theaudin M, Lozeron P, Algalarrondo V, Lacroix C, Cauquil C, Labeyrie C, et al. Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas. Eur J Neurol. 2019;26(3):497\u2013e36.","journal-title":"Eur J Neurol"},{"issue":"6","key":"1252_CR66","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/ana.24519","volume":"78","author":"LL Mariani","year":"2015","unstructured":"Mariani LL, Lozeron P, Theaudin M, Mincheva Z, Signate A, Ducot B, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol. 2015;78(6):901\u201316.","journal-title":"Ann Neurol"},{"issue":"6","key":"1252_CR67","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","volume":"87","author":"AS Carr","year":"2016","unstructured":"Carr AS, Pelayo-Negro AL, Evans MR, Laura M, Blake J, Stancanelli C, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry. 2016;87(6):620\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1252_CR68","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387\u2013404.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1252_CR69","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","volume":"91","author":"P Lozeron","year":"2018","unstructured":"Lozeron P, Mariani LL, Dodet P, Beaudonnet G, Theaudin M, Adam C, et al. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology. 2018;91(2):e143\u2013e52.","journal-title":"Neurology"},{"issue":"5","key":"1252_CR70","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","volume":"88","author":"A Cortese","year":"2017","unstructured":"Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry. 2017;88(5):457\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1252_CR71","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3109\/13506129909007313","volume":"6","author":"K Tashima","year":"1999","unstructured":"Tashima K, Suhr OB, Ando Y, Holmgren G, Yamashita T, Obayashi K, et al. Gastrointestinal dysfunction in familial amyloidotic polyneuropathy (ATTR Val30Met)--comparison of Swedish and Japanese patients. Amyloid. 1999;6(2):124\u20139.","journal-title":"Amyloid"},{"issue":"7","key":"1252_CR72","first-page":"417","volume":"78","author":"LE Steen","year":"1983","unstructured":"Steen LE, Oberg L. Familial amyloidosis with polyneuropathy: roentgenological and gastroscopic appearance of gastrointestinal involvement. Am J Gastroenterol. 1983;78(7):417\u201320.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1252_CR73","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00428-016-1916-y","volume":"468","author":"S Freudenthaler","year":"2016","unstructured":"Freudenthaler S, Hegenbart U, Schonland S, Behrens HM, Kruger S, Rocken C. Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patients. Virchows Arch. 2016;468(5):569\u201377.","journal-title":"Virchows Arch"},{"issue":"1","key":"1252_CR74","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1365-2796.1998.00247.x","volume":"243","author":"S Yoshimatsu","year":"1998","unstructured":"Yoshimatsu S, Ando Y, Terazaki H, Sakashita N, Tada S, Yamashita T, et al. Endoscopic and pathological manifestations of the gastrointestinal tract in familial amyloidotic polyneuropathy type I (Met30). J Intern Med. 1998;243(1):65\u201372.","journal-title":"J Intern Med"},{"issue":"12","key":"1252_CR75","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1365-2982.2012.01991.x","volume":"24","author":"J Wixner","year":"2012","unstructured":"Wixner J, Karling P, Rydh A, Hornsten R, Wiklund U, Anan I, et al. Gastric emptying in hereditary transthyretin amyloidosis: the impact of autonomic neuropathy. Neurogastroenterol Motil. 2012;24(12):1111\u2013e568.","journal-title":"Neurogastroenterol Motil"},{"issue":"5","key":"1252_CR76","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","volume":"33","author":"J Nativi-Nicolau","year":"2018","unstructured":"Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018;33(5):571\u20139.","journal-title":"Curr Opin Cardiol"},{"issue":"24","key":"1252_CR77","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac Transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312.","journal-title":"Circulation"},{"issue":"3","key":"1252_CR78","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/CIRCIMAGING.113.001396","volume":"7","author":"RH Falk","year":"2014","unstructured":"Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014;7(3):552\u201362.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"1252_CR79","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3109\/13506120903421850","volume":"16","author":"B Do Amaral","year":"2009","unstructured":"Do Amaral B, Coelho T, Sousa A, Guimaraes A. Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid. 2009;16(4):232\u20138.","journal-title":"Amyloid"},{"issue":"10","key":"1252_CR80","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","volume":"113","author":"NM Fine","year":"2014","unstructured":"Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113(10):1723\u20137.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1252_CR81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mus.21226","volume":"39","author":"JD England","year":"2009","unstructured":"England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, et al. Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Muscle Nerve. 2009;39(1):116\u201325.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1252_CR82","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","volume":"13","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1252_CR83","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403\u2013E12.","journal-title":"Hum Mutat"},{"issue":"12 Suppl 3","key":"1252_CR84","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","volume":"84","author":"JP Donnelly","year":"2017","unstructured":"Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl 3):12\u201326.","journal-title":"Cleve Clin J Med"},{"key":"1252_CR85","volume-title":"3021, editor. 21st Annual Scientific Meeting HFSA supplement","author":"A Ikram","year":"2017","unstructured":"Ikram A, Sperry B, Reyes B, Seitz W, Hanna M. Carpal Tunnel Syndrome and Amyloid Cardiomyopathy. In: 3021, editor. 21st Annual Scientific Meeting HFSA supplement; 2017."},{"key":"1252_CR86","volume-title":"A Physician\u2019s Guide to Transthyretin Amyloidosis","author":"T Coelho","year":"2008","unstructured":"Coelho T, Ericzon BG, Falk R, Grogan D, Ikeda SI, Maurer M, et al. A Physician\u2019s Guide to Transthyretin Amyloidosis. 2008."},{"issue":"47","key":"1252_CR87","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","volume":"37","author":"A Galat","year":"2016","unstructured":"Galat A, Guellich A, Bodez D, Slama M, Dijos M, Zeitoun DM, et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J. 2016;37(47):3525\u201331.","journal-title":"Eur Heart J"}],"container-title":["BMC Family Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-020-01252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-020-01252-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-020-01252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T19:14:33Z","timestamp":1632338073000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-020-01252-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1186\/s12875-020-01252-4","relation":{},"ISSN":["1471-2296"],"issn-type":[{"value":"1471-2296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable since patient medical information was not directly included in this study. All data analyzed during this study were generated from cited published articles.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MG reports personal fees from Ionis\/Akcea, Alnylam, Prothena, Celgene, Janssen, Spectrum, Annexon, Appellis, Amgen, Medscape, Physicians Education Resource, AbbVie (Data Safety Monitoring board), Research to Practice; speaker fees from Teva, Johnson and Johnson, Medscape, DAVA Oncology; advisory boards for Pharmacyclics and Proclara; royalties from Springer Publishing; and grant funding from Amyloidosis Foundation, International Waldenstrom Foundation, Spectrum, and the National Cancer Institute (SPORE MM SPORE 5P50 CA186781\u201304).DA reports grants from Alnylam and Pfizer and personal fees from Prothena, GlaxoSmithKline, Alnylam, and Pfizer.YA, JMB, and PNH have nothing to disclose.SB reports personal fees from Pfizer.TC was paid per protocol for clinical trials from FoldRx, Pfizer, Ionis, and Alnylam and received grants from FoldRx and Pfizer; received support from Pfizer, Ionis, Biogen, and Alnylam to attend scientific meetings; and has presented on behalf of Pfizer, Alnylam, GlaxoSmithKline, Prothena, and Ionis\/Akcea and received honoraria.RLC reports consulting fees from Prothena, Janssen, Amgen, Takeda, Sanofi-Aventis, Unum, Caelum and reports grant\/research support from Prothena, Janssen, Takeda, and Karyopharm.TD reports grants from Pfizer and Alnylam Pharmaceuticals and reports personal fees from Ionis Pharmaceuticals, Prothena Group, and GlaxoSmithKline.SD reports personal fees from Pfizer, GE Healthcare, and Advanced Accelerator Applications.BMD reports personal fees from Pfizer and Alnylam Pharmaceuticals.MF reports a grant from GlaxoSmithKline and reports personal fees from British Heart Foundation, Pfizer, Alnylam Pharmaceuticals, and Prothena.JDG participated in advisory boards for Alnylam Pharmaceuticals and GlaxoSmithKline.MG reports grants from Eidos Therapeutics, Pfizer, Alnylam Pharmaceuticals, and Prothena.IL has received honoraria from Akcea Therapeutics.AVK reports personal fees from Akcea Therapeutics, Eidos Therapeutics, Pfizer, Alnylam Pharmaceuticals.FLR reports grants from Pfizer and personal fees from Pfizer and Alnylam Pharmaceuticals.OBS received honoraria and travel and consultancy fees from Ionis\/Akcea, Alnylam, Prothena, and Intellia.MSM reports grants from Pfizer and Alnylam Pharmaceuticals and reports personal fees from Akcea Therapeutics, Ionis Pharmaceuticals, Prothena Corp, Pfizer, Alnylam Pharmaceuticals, Eidos Therapeutics, and GlaxoSmithKline.JNN reports grants from Pfizer, Eidos Therapeutics, and Akcea Therapeutics and personal fees from Pfizer, Akcea Therapeutics, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals.CCQ reports personal fees from Alnylam Pharmaceuticals.CR reports grants from Pfizer and personal fees from Pfizer and Alnylam Pharmaceuticals.RW reports grants from Pfizer and Eidos Therapeutics and reports personal fees from Alnylam Pharmaceuticals, Pfizer, and Eidos Therapeutics.GM has received honoraria from Janssen and Prothena; travel support from Prothena and Celgene; and consulting fees from Millennium, Pfizer, Janssen, Prothena, and Ionis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}